<div>In a study published on the bioRxiv preprint server, researchers from the University of P&eacute;cs, University of Vienna, and CEBINA GmbH, Vienna, show the ability of the antihistamine azelastine to inhibit SARS-CoV-2 infection in human nasal tissue in vitro.</div>